CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Items 501–600 of 718
Berclaz, L. M., Altendorf-Hofmann, A., Lindner, L. H., Burkhard‐Meier, A., Gioia, D. D., Dürr, H. R., Klein, A., Albertsmeier, M., Schmidt-Hegemann, N.-S., Klauschen, F., et al. (2023) · Cancers · doi:10.3390/cancers15102735 · Cited by 7
“Depending on the interplay with its interacting ligands such as CEACAM1 or lectin galectin 9, TIM-3 is differently phosphorylated and either permissive or inhibitory to T cell activation [21,22].”
BackgroundLi, N., Yang, J., Wang, X., Wang, H., Guan, B., & Zhou, C. (2015) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2015.10.012 · Cited by 6
“expression [28].”
Co-inhibitory receptors, transcription factors and tolerance
Mohammadzadeh, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106572 · Cited by 6
Regulation of Tim-3 function by binding to phosphatidylserine
Kane, L. (2021) · Biochemical Journal · doi:10.1042/bcj20210652 · Cited by 6
Pfeifhofer‐Obermair, C., Brigo, N., Volani, C., Tymoszuk, P., Demetz, E., Engl, S., & Weiß, G. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105910 · Cited by 6
“11,12 However, at the same time, TIM-3 acts as a key factor in T cell dysfunction and exhaustion.”
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 13
“TIM-3 marks terminally exhausted T cells and impairs function via ligands such as galectin-9 and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), disrupting the immunological synapse, promoting anergy, and triggering cell death [96, 97, 156– 158].”
Gu, L., Zhang, Q., Liang, Q., Peng, C., Wang, Y., Wang, C., Li, Z., Tan, Y., Zhou, Y. H., Bi, Q., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70978-z · Cited by 8
“Disruption of CEACAM1 – TIM-3 interactions has been shown to enhance PD-1 ef fi cacy 22,23 .”
InfluentialSelf-citationPost-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency
Baldrich, A., Althaus, D., Menter, T., Hirsiger, J. R., Köppen, J., Hupfer, R., Juškevičius, D., Konantz, M., Bosch, A. J. T., Drexler, B., et al. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01667-z · Cited by 5
“Homozygous carriage of the TIM-3 Thr101Ile missense variant (rs147827860, not the same variant as detected in our patient) has been linked to human IBD [33].”
BackgroundKong, H., Yang, Q., Wu, C.-W. G., Wu, X., Yan, X., Huang, L., Chen, L., Zhou, Z., Wang, P., & Jiang, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0270 · Cited by 5
“In recent years, TIM-3 has emerged as a promising target for cancer immunotherapy, and anti-TIM-3 therapies are being explored as a means of reversing T-cell exhaustion and restoring antitumor immunity (32, 34, 35).”
Structural aspects of CEACAM1 interactions
Gandhi, A. K., Huang, Y., Sun, Z., Kim, W. M., Kondo, Y., Hanley, T., Beauchemin, N., & Blumberg, R. S. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14357 · Cited by 7
Self-citationStructural insights into antibody-based immunotherapy for hepatocellular carcinoma
Shah, M., Hussain, M. S., & Woo, H. G. (2025) · Genomics & Informatics · doi:10.1186/s44342-024-00033-0 · Cited by 7
Structural analysis of human CEACAM1 oligomerization
Gandhi, A. K., Sun, Z.-Y. J., Huang, Y., Kim, W. M., Yang, C., Petsko, G. A., Beauchemin, N., & Blumberg, R. S. (2022) · Communications Biology · doi:10.1038/s42003-022-03996-4 · Cited by 5
Self-citationCurrent Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment
Farhangnia, P., Ghomi, S. M., Mollazadehghomi, S., & Delbandi, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_163 · Cited by 5
Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer
Lei, X., Wang, Y., Broens, C., Borst, J. G., & Xiao, Y. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.07.006 · Cited by 5
Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
Dong, D., Xue, Y., Liu, H., Xu, J., Guo, J., Guo, W., Li, X., Wang, F., Zhang, D., Liu, K., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.01.007 · Cited by 9
Xu, W., Qi, F., Jiao, R., Zheng, L., Zhang, Y., Hou, D., Liu, Y., & Kang, Z. (2020) · Precision Medical Sciences · doi:10.1002/prm2.12007 · Cited by 5
“Furthermore, binding of TIM-3 to its ligand galectin-9 triggers Th1 cells died and induces peripheral tolerance, suggesting an inhibitory effect of TIM-3 in immune response.(7,8) In fact, TIM-3 is identified as an important negative regulatory factor of CD4+ and CD8+ T-cells.”
BackgroundHosseini-Valiki, F., Taghiloo, S., Tavakolian, G., Amjadi, O., Tehrani, M., Hedayatizadeh‐Omran, A., Alizadeh‐Navaei, R., Zaboli, E., Shekarriz, R., & Asgarian‐Omran, H. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.9.2615 · Cited by 4
“…as the major ligand of this receptor, results in phosphorylation of Y256 and Y263 and releasing of Bat3 from the Tim-3 tail, thus stimulating Tim-3 mediated suppression of T-cells by promoting binding of Src kinases and modulation of TCR signaling (Rangachari et al., 2012; Huang et al., 2015).”
BackgroundClinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy
Kikushige, Y. (2022) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2022-010 · Cited by 6
CEACAM1 as a molecular target in oral cancer
Ma, S., Wang, Z., Li, C., Liu, Z., Zhang, X., Li, L., An, F., & Qiao, X. (2023) · Aging · doi:10.18632/aging.204960 · Cited by 5
Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
Branca, M., Orso, S., Molinari, R., Xu, H., Guerrier, S., Zhang, Y., & Mili, N. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000412 · Cited by 5
Hussain, T., Saha, D., & Chakraborty, A. (2025) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.7.113 · Cited by 5
Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target
Ma, H., Ren, S., Meng, Q., Su, B., Wang, K., Liu, Y., Wang, J., Ding, D., & Li, X. (2023) · Archives of Virology · doi:10.1007/s00705-023-05842-2 · Cited by 4
Zheng, W., Ao, D., Cao, Q., Liu, A., Lv, M., Sun, Z., Zhang, H., Zheng, W., Chen, N., & Zhu, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132018 · Cited by 4
Tim-3 promotes viral infection by suppressing the USP25-TRAF3-IRF7 signaling pathway
Du, L., Chen, J., Du, C., Chen, J., Wang, Z., Bao, B., Zhonglin, L. V., Chen, X., Liang, M., Wang, L., et al. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.104930 · Cited by 4
Targeting the hippo pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Meng, Y. G., Chang, X., Cao, S., Ma, P., Ouyang, Y. Q., & Dong, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115067 · Cited by 5
Zhang, S., Jiang, M., Wu, C., Wang, H., & He, F. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120280 · Cited by 4
Ochman, B., Kot, A., Mielcarska, S., Kula, A., Dawidowicz, M., Hudy, D., Szrot, M., Piecuch, J., Waniczek, D., Czuba, Z. P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146735 · Cited by 5
TIM-3, a potential target for sepsis therapy
Huang, S., Huang, X., Feng, X., Wang, R., Liao, F., Liu, D., Sun, J., Zhang, H., Yu, A., & Zeng, L. (2025) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2025.08.001 · Cited by 4
“47 Kared et al. 49 demonstrated that CEACAM-1 suppresses NK-cell function by inhibiting the transcription Factor T-bet, but TIM-3 blockade reverses this suppression; as a result, cytokine secretion and cytotoxic activity are restored.”
Proteostasis of immune checkpoint receptors
Tey, P. Y., Urbé, S., & Clague, M. J. (2025) · Biochemical Journal · doi:10.1042/bcj20253299 · Cited by 4
“Another homozygous TIM-3 mutation (Thr101Ile), found in patients with inflammatory bowel disease, reportedly prevents TIM-3 glycosylation and trafficking to the plasma membrane [251].”
TIM-3+ Macrophages: Insights into Their Role in Cancer and Inflammation
Maksimova, А. А., Викторовна, Т. Т., & Chernykh, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020840 · Cited by 6
Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor
Hajihassan, Z., Saray, M. M., & Yaseri, A. (2023) · Payam Marafat Journal of Social Sciences · doi:10.61186/ibj.3874 · Cited by 4
“In chronic viral infections and in the tumor microenvironment, the binding of TIM-3 and CEACAM1 leads to T-cell exhaustion [8,9] .”
BackgroundZhou, D., Liu, L., Liu, J., Li, H., Zhang, J., & Cao, Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051210 · Cited by 5
“While Gal-9 was the inaugural ligand identified for Tim-3, subsequent research has unveiled other ligands, such as phosphatidylserine (PtdSer), high mobility histone B1 (HMGB1) [35], and carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) [36] (Figure 3).”
BackgroundInhibitory Checkpoint Receptor TIM-3 as a Regulator of the Functional Activity of Dendritic Cells
Викторовна, Т. Т., & Chernykh, E. R. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06175-z · Cited by 4
“For example, the complex formed by TIM-3 and CEACAM1 is involved in the reg - ulation of autoimmunity and the antitumor immune response [17], but how TIM-3/CEACAM1-axis can regulate the functional activity of DCs is unknown.”
The Promise of Epigenetics. Has It Delivered New Insights?
Cho, J. H. (2016) · Digestive Diseases · doi:10.1159/000442919 · Cited by 4
Expression of Galectin-9-related immune checkpoint receptors in B-cell acute lymphoblastic leukemia.
Akbar, A., Asgarian‐Omran, H., Valadan, R., Dindarloo, M. M., Najafi, A., Kahrizi, A., Poursheikhani, A., Karami, H., Naderi, M., Billandi, S. S., et al. (2023) · PubMed Central · doi:10.22038/ijbms.2023.73159.15901 · Cited by 6
Pathways and molecules for overcoming immunotolerance in metastatic gastrointestinal tumors
Gan, Q., Li, Y., Li, Y., Liu, H., Chen, D., Liu, L., & Peng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359914 · Cited by 6
“Consequently, targeting both CEACAM1 and TIM-3 concurrently holds promise as a strategy to enhance anti-tumor immune responses in CRC, as evidenced by successful outcomes in CRC mouse models (151).”
BackgroundInfluence of SLC40A1 on Cytokine Interactions and Immune Infiltration in Glioblastoma
Jiang, J., Duan, R., Zhu, J., Yan, J., Ye, J., & Luo, C. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08789-y · Cited by 4
Kumar, S., & Das, A. (2022) · Vegetos · doi:10.1007/s42535-022-00363-w · Cited by 5
Cross-species insights into CEACAM1 autoantibodies as diagnostic biomarkers for mammary cancer
Rathinavelu, P. K., Saxena, S., Shrivastava, S., Kumar, V., Khan, O., Nagappan, S., Saminathan, M., & Chittalangia, R. K. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152735 · Cited by 3
Khaled, C., Kim, M., & Min, B. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01562-6 · Cited by 4
“Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is both a cis and trans ligand important for the tolerance-inducing property of Tim3 114 .”
Tsotridou, E., Vasileiou, E., Mantadakis, E., & Tragiannidis, A. (2021) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525719666210510171132 · Cited by 3
Ubiquitination and degradation of MHC-II by Tim-3 inhibits antiviral immunity
Zhou, J., Lv, Z., Liu, M., Du, C., Du, L., Gao, Z., Jiang, Z., Wang, L., Wang, S., Liang, M., et al. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104889 · Cited by 3
Wu, N., Pei, X., Cai, W., Ye, X., & Lu, W. (2025) · International Journal of Hyperthermia · doi:10.1080/02656736.2025.2516502 · Cited by 5
“Tim-3 antibodies can activate the PI3K/AKT/mTOR and MAPK/ERK pathways by blocking the binding of Tim-3 to its ligands (such as Galectin-9, CEACAM-1), promoting the proliferation, activation, and differentiation of CD8 + T cells, thereby restoring their anti-tumor activity [25,51–53].”
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
Zheng, R., Li, Y., Shi, K., Pan, Y., Liu, K., Song, J., & Li, L. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101206 · Cited by 4
“…four distinct ligands: galectin-9 [63], phosphatidylserine (PtdSer) [64], High-mobility group box 1 (HMGB1), which binds necrotic tumor-derived nucleic acids to activate dendritic cell-mediated innate immunity [65], and CEACAM1, an autologous T-cell ligand that suppresses T-cell activation [66].”
Nalini, R., Roshandel, E., Ardakani, M. T., Kazemi, M. H., Nazari, H. G., Hajifathali, A., & Soleimani, M. (2022) · International Journal of Cancer Management · doi:10.5812/ijcm-120888 · Cited by 3
Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
Li, J., Chen, Y., Fan, Y., Wang, H., Mu, W., & Liu, X. (2023) · Discover Oncology · doi:10.1007/s12672-023-00638-x · Cited by 3
“Interestingly, CEACAM1-Tim3 interactions notably enhance the negative immunoregulatory capacity of Tim-3 and promote tumour evasion of immunosurveillance and immune killing [12].”
BackgroundHuang, Y., Zhang, W., Xu, C., Li, Q., Zhang, W., Xu, W., & Zhang, M. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003196 · Cited by 3
Self-citationThe kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns
Torki, E., Gharezade, A., Doroudchi, M., Sheikhi, S., Mansury, D., Sullman, M. J. M., & Fouladseresht, H. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01188-w · Cited by 4
“The TIM-3-Ceacam1 interaction is required to promote the stable expression of TIM-3 on immune cells [68].”
BackgroundRiess, J. W., Lara, M. S., de Rodas, M. L., Luxardi, G., Herbert, S. M., Shimoda, M., Kelly, K. L., Meerlev, A., Moore, E., Beckett, L. A., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100706 · Cited by 7
Immune Checkpoint Inhibitors in Cancer Immunotherapy
Hussain, F. H. N., & Raza, A. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch004 · Cited by 3
Xu, S., Yang, L., He, Y., Chen, Y., Qin, F., & Hu, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-02673-2 · Cited by 3
Tang, X., Xue, J., Li, X., Zhang, J., & Zhou, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1623315 · Cited by 4
Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy
Guo, Q. (2018) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/301/1/012020 · Cited by 3
“Other ligands, such as Ceacam-1 and HMGB-1 are also reported to bind to Tim-3 [13].”
BackgroundEnhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistancePreprint
Maitituoheti, M., Shi, A., Tang, M., Ho, L., Terranova, C. J., Galani, K., Keung, E. Z.-Y., Creasy, C. A., Wu, M., Chen, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.31.506051 · Cited by 3
Yan, J., Liu, B.-B., Yang, Y., Liu, M., Wang, H., Deng, Z.-Q., & Zhang, Z. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i12.2212 · Cited by 3
“Moreover, TIM3, which acts with its ligand CEA cell adhesion molecule 1, can suppress T cells, thereby downregulating antitumor immunity[37,38].”
Chen, X., Li, S., Cao, L.-X., Chen, S.-X., Lin, Q., & Zhong, S.-L. (2025) · Discover Oncology · doi:10.1007/s12672-025-01768-0 · Cited by 2
“In a mouse model of colorectal cancer, blocking HAVCR2 has been shown to enhance anti-tumor responses and promote tumor clearance [41].”
Liu, J., Chen, J., Chen, S., Huang, Y., Xu, K., Cai, D., Liao, X., You, R., Xu, X., Wang, X., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102461 · Cited by 3
“Characterization of age-associated exhausted CD8 ⁺ T cells defined by increased expression of Tim-3 and PD-1 [38,39].”
Self-citationGalectin-9: diverse roles in skin disease
Wang, L., Zhang, C., Ji, J., & Jiao, Q. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1614277 · Cited by 2
“Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM-1) acts as a heterotypic binding partner for TIM-3, essential for its T-cell suppressive activity (10).”
Matsuida, H., Mimura, K., Nakajima, S., Saito, K., Hayashishita, S., Takiguchi, C., Nirei, A., Kikuchi, T., Hanayama, H., Okayama, H., et al. (2025) · Cells · doi:10.3390/cells14151212 · Cited by 2
“It was known that CEACAM-1 and CD155 are ligands for TIM-3 and TIGIT, which are major inhibitory immune checkpoint pathways, respectively [23,24].”
Du, Z., Yi, J., Li, J., You, H.-R., You, Z., Huang, Z.-A., & Huang, Y. (2025) · Knowledge-Based Systems · doi:10.1016/j.knosys.2025.114416 · Cited by 4
Self-citationThe combination of CD8 and TIM3 expression predicts survival outcomes in hepatocellular carcinoma
Noma, T., Wada, Y., Nishi, M., Teraoku, H., Yamada, S., Saito, Y., Ikemoto, T., Morine, Y., & Shimada, M. (2025) · The Journal of Medical Investigation · doi:10.2152/jmi.72.354 · Cited by 3
TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy
Wang, L., Shen, H., Jiang, B., Wang, X., Yang, P., & Sun, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02693 · Cited by 3
Revamping Hepatocellular Carcinoma Immunotherapy: The Advent of Microbial Neoantigen Vaccines
Liang, J., Liao, Y., Tu, Z., & Liu, J. (2024) · Vaccines · doi:10.3390/vaccines12080930 · Cited by 2
“TIM3, by binding to galectin 9 or CEACAM1, induces CD8 + T-cell apoptosis and exhaustion [39].”
BackgroundInhibition of CEACAM1 expression in cytokine-activated neutrophils using JAK inhibitors
Matsumoto, H., Sudo, R., Fujita, Y., Onizawa, M., Saito, K., Sumichika, Y., Yoshida, S., Temmoku, J., Matsuoka, N., Asano, T., et al. (2024) · BMC Immunology · doi:10.1186/s12865-024-00656-6 · Cited by 2
TIM3 in COVID-19; A potential hallmark?
Zamani, M. R., & Šácha, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40386 · Cited by 2
TIM proteins and microRNAs: distinct impact and promising interactions on transplantation immunity
Tao, J., Shen, X., Qian, H., Ding, Q., & Wang, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1500228 · Cited by 3
“TIM-3 serves as a suppressor molecule involved in T cell activation and is a marker of T cell depletion in tumors and chronic viral infections (57).”
Li, S., Pan, Y., Ye, R., Wang, Y., & Li, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113717 · Cited by 2
Choi, W., Lee, W., Kim, Y.-W., Lee, S.-J., Lee, G. K., Park, S.-J., Ju, S., Kim, S., Lee, C., & Han, J. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108448 · Cited by 3
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
Poorkhani, A., Tajaldini, M., Ahmadi, F., Tahmasebifar, A., Azadehrah, M., Azadehrah, M., Ghamoushiramandi, A., Amiri, R. S., & Khori, V. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04131-w · Cited by 6
“The binding of Tim-3 with its ligands such as Galectin-9 and Ceacam-1 activates the signaling pathway through the phosphorylation of Y256 and Y263, resulting in the detachment of Bat3 (Rangachari et al. 2012; Huang et al. 2015b).”
Site-to-site cross-talk in OST-B glycosylation of hCEACAM1-IgV
Williams, R. V., Huang, C. C., McDermott, C. M., Ahmed, T., Columbus, L. M., Moremen, K. W., Prestegard, J. H., & Amster, I. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202992119 · Cited by 2
“Also, unglycosylated versions of hCEACAM1-IgV readily fold, and several crystal structures of the bacterially expressed protein have been determined (18, 19).”
BackgroundImmunology and Immunotherapy of Colorectal Cancer
Varela‐Calviño, R., & Cordero, O. J. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_11 · Cited by 2
Tumor immunotherapy – A lot to learn from Keratoacanthoma
Patil, S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109719 · Cited by 2
Recent advancements in immunotherapy for colorectal cancer
De, A., Kuppusamy, G., Bhuyan, N. R., Sauraj, & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00011-8 · Cited by 3
Expression of Tim-3 drives naïve Treg to an effector-like state with enhanced suppressive activityPreprint
Banerjee, H., Nieves-Rosado, H. M., Kulkarni, A., Murter, B., Chandran, U. R., Chang, A., Szymczak-Workman, A. L., Vujanovic, L. N., Ferris, R. L., & Kane, L. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.230714 · Cited by 2
“The inhibitory signaling of Tim-3 has been postulated to proceed through in trans interactions or signaling through various molecules, including Bat3, CD45, CEACAM-1 and a long-noncoding RNA (Clayton et al., 2014; Huang et al., 2014; Ji et al., 2018; Rangachari et al., 2012).”
BackgroundWu, S., Du, X., Lou, G., Yu, S., Lai, K., Qi, J., Ni, S., Chen, Z. J., & Chen, F. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07841-1 · Cited by 2
“Binding of Tim-3 and CEACAM1 promotes temporal differences in Restimulation-induced cell death (RICD) sensitivity in the effector T cell response [35], which plays a key role in regulating anti-tumour immunity [34] and antiviral responses [36].”
BackgroundKotnala, S., Dhasmana, A., Dhasmana, S., Haque, S., Yallapu, M. M., Tripathi, M. K., Jaggi, M., & Chauhan, S. C. (2023) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2023048056 · Cited by 2
Next generation immune checkpoints
Perez, N. M., Moziak, K., & Martin, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90009-2 · Cited by 1
Nuclear Molecular Imaging for Evaluating T Cell Exhaustion
Zhou, H., Bao, G., Zhao, J., & Zhu, X. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00970 · Cited by 1
Ying, X., Lou, Y., Wu, Y., & Hu, W. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1622511 · Cited by 1
“TIM-3 interacts with multiple ligands, such as Galectin-9 (Yang et al., 2021), CEACAM1(Huang et al., 2015), phosphatidylserine (PtdSer) (DeKruyff et al., 2010), and HMGB1 (Tang and Lotze, 2012), promoting tumor immune tolerance and CD8 + T-cell exhaustion, thus facilitating tumor progression (Dixon et al., 2021).”
Tiyamanee, W., Okagawa, T., Yamada, S., Ikehata, M., Nakamura, H., Inoue, M., Maekawa, N., Kato, Y., Shiro, M., Ohashi, K., et al. (2025) · Veterinary Sciences · doi:10.3390/vetsci12090810 · Cited by 3
“Furthermore, TIM-3 binds to multiple ligands, including galectin-9 [17], phosphatidylserine, high-mobility group box 1 (HMGB-1) [18], and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) [19].”
Identifying Hub Genes Associated with Sex Disparities in Prolactinomas
Zhang, Y., Peng, Y., Wang, C., Liang, H., Li, S., & Yang, H. (2025) · Genetic Testing and Molecular Biomarkers · doi:10.1177/19450265251375945 · Cited by 1
Brydon, J., Krejčíř, R., Grima, M., Zavadil-Kokas, F., Kuncova, Z., Sousan, S., Pflughaupt, R. L., Thomson, J. R., Davies, P., Senior, E., et al. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.116033 · Cited by 1
Kim, M., Gu, T., Seo, H., Moon, Y., Borcherding, N. C., Kolb, R. H., Kim, Y., Yun, Y., Song, W., Lee, C.-Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680437 · Cited by 1
TIM-3 in AML: pathogenic roles and therapeutic targetability
Zhong, L., & Samarkhazan, H. S. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02133-3 · Cited by 3
TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal
Hjazi, A. M. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04337-9 · Cited by 1
“Galectin-9 is the best-established TIM-3 ligand in AML, but TIM-3 is not limited to galectin-9; phosphatidylserine, HMGB1, and CEACAM1 can also engage TIM-3 in a context-dependent manner [39, 56, 68].”
Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease
Hasegawa, Y., Teshima, T., & Hashimoto, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1838922 · Cited by 1
“TIM-3 is also expressed on activated and exhausted T cells, where it functions as an inhibitory immune checkpoint (94, 95).”
Innate immunity in tumors: From mechanisms to therapeutics
Hu, Y., Wang, X., Ma, H., & Zheng, X. B. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004116 · Cited by 1
Targeting the glioblastoma-initiating cell-associated antigens
(2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1329 · Cited by 1
The major clinical components of cancer immunotherapy (modulating cell-mediated immune mechanisms)
Bonifant, C. L., & Burns, W. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00019-8 · Cited by 1
TIM-3 blockade: immune and targeted therapy in DIPG
Hu, Y., Hu, P., & Peng, X. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.014 · Cited by 1
Tim-3 Is Not Required for Establishment of CD8+ T Cell Memory to Lymphocytic Choriomeningitis Virus
Manandhar, P., Szymczak-Workman, A. L., & Kane, L. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300401 · Cited by 1
Gayen, S., Mukherjee, S., Dasgupta, S., & Roy, S. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02022-8 · Cited by 1
“…such as the soluble lectin galectin 9 (Gal-9) and the adhesion mol - ecule carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1), both are expressed in tumor cells which can bind with TIM3 receptor on immune cells to fostering the inhibitory effects on T cell activation [ 64].”
Fleckenstein, J. M., Najjar, S. M., Zimmermann, W., Hauck, C. R., Nguyen, Q., Mejías‐Luque, R., Bhattacharyya, A., McCarthy, A. J., Sarkar, A., Kujawski, M., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14355 · Cited by 1
“47 Using TIM-3Tg/Ceacam1KO double-mutant mice, the functional significance of host CEACAM1 signalling was confirmed, as its deficiency at the recipient site caused significantly higher cellular death in wild-type liver grafts than in Ceacam1-proficient controls.”
Targeting the Immune Checkpoint in Bladder Cancer
Mercinelli, C., Tateo, V., Crupi, E., Cigliola, A., & Necchi, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-68505-7_23 · Cited by 1
Targeting Ischemia-reperfusion injury in liver transplant rejuvenation
Dery, K. J., Kaldas, F. M., & Kupiec‐Weglinski, J. W. (2025) · Transplantation Reports · doi:10.1016/j.tpr.2025.100176 · Cited by 2
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
Juneja, V. R., LaFleur, M. W., Manguso, R. T., & Sharpe, A. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_1 · Cited by 2
Kammerer, R., Herse, F., & Zimmermann, W. (2016) · Springer eBooks · doi:10.1007/978-3-319-41324-2_3 · Cited by 1
Tseng, D., Schultz, L. M., Pardoll, D. M., & Mackall, C. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00006-2 · Cited by 3
Hub Gene Screening and Prognostic Modeling of Lung Cancer: An Integrated Bioinformatics Study
Bai, H., & Huang, X. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5110683 · Cited by 1
“HAVCR2 is a member of the immunoglobulin superfamily as well as the TIM protein family [21].”
BackgroundRetractedThe Role of Immune Checkpoints in Cancer Progression
Prasetya, R. A., & Wulansari, D. D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105628 · Cited by 1
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.